Dronedarone: What It Is. Dose. Prescribing Information

Dronedarone. Introduction

Dronedarone is a Class III antiarrhythmic developed as a non-iodinated analogue of amiodarone, with the aim of keeping part of its efficacy while avoiding its extracardiac toxicity. Although it shares many of amiodarone's pharmacological effects, it is less potent and lacks some of the thyroid and pulmonary risks.

It is used mainly to prevent recurrences of atrial fibrillation (AF) or atrial flutter, but its safety depends on careful patient selection, since it has been shown to increase mortality in advanced heart failure.

Pharmacology and Mechanism of Action of Dronedarone

  • Potassium current blockade (IKr, IKs): Prolongs the action potential and the QT.
  • Sodium and calcium channel blockade: Slows conduction and reduces automaticity.
  • β-adrenergic antagonism: Negative chronotropic and dromotropic effects.

Unlike amiodarone, dronedarone has no iodine in its structure, which reduces thyroid and pulmonary toxicity.

Pharmacokinetics of Dronedarone

  • Oral bioavailability: Low (≈15%), increased with fatty meals.
  • Half-life: 13–19 hours, much shorter than that of amiodarone.
  • Metabolism: Hepatic, mainly CYP3A4.
  • Excretion: Faecal, minimal renal elimination.

Dronedarone Dosing

  • Usual dose: 400 mg orally every 12 hours, taken with food.
  • Does not require a loading dose.
  • Contraindications: Severe hepatic impairment and combination with potent CYP3A4 inhibitors. Stopping treatment is recommended if QTc exceeds 500 ms.

Clinical Uses of Dronedarone

  • Prevention of recurrences of paroxysmal or persistent atrial fibrillation.
  • Reduction of cardiovascular hospitalisations in patients with non-permanent AF (ATHENA trial).
  • Not indicated for acute pharmacological cardioversion.

Clinical limitations

  • Contraindicated in advanced heart failure or recent decompensation (ANDROMEDA trial: increased mortality).
  • Less effective than amiodarone at preventing recurrences, although better tolerated outside the heart.

Clinical Evidence on Dronedarone

  • ATHENA: reduction in cardiovascular hospitalisations in non-permanent AF.
  • ANDROMEDA: increased mortality in advanced HF → absolute contraindication in that setting.
  • DIONYSOS: comparison with amiodarone → less effective, but less thyroid and pulmonary toxicity.

Adverse Effects of Dronedarone

  • Cardiac: QTc prolongation, risk of torsades (although lower than with dofetilide/ibutilide).
  • Gastrointestinal: diarrhoea, nausea, abdominal pain. Hepatic: cases of severe hepatotoxicity and fulminant liver failure.
  • Renal: reversible rise in serum creatinine due to inhibition of tubular secretion.

Dronedarone Interactions

  • Inhibits P-gp → increases levels of digoxin.
  • Metabolised by CYP3A4 → interactions with potent inhibitors/inducers (clarithromycin, ketoconazole, rifampicin).
  • Take care with oral anticoagulants and statins (increased plasma levels).

Monitoring During Dronedarone Treatment

  • ECG: QTc check at the start and during follow-up.
  • Liver function: periodic tests because of the risk of hepatotoxicity.
  • Kidney function: serum creatinine monitoring.
  • Concomitant drugs: always check for interactions.

Contraindications to Dronedarone

  • IHeart failure that is advanced or recently decompensated.
  • Baseline QTc ≥500 ms.
  • AV block second or third degree without a pacemaker.
  • ILiver failure severe.
  • Pregnancy and breastfeeding.

Conclusion on Dronedarone

Dronedarone is an attempt to obtain an "amiodarone light": an effective drug that is better tolerated in the long term. Its iodine-free profile reduces thyroid and pulmonary complications, but at the cost of lower antiarrhythmic potency. Its use should be limited to patients with non-permanent AF, good ventricular function and no advanced heart failure.

References

Merino JL, Tamargo J, Blomström-Lundqvist C, et al. Practical compendium of antiarrhythmic drugs: a clinical consensus statement of the European Heart Rhythm Association of the European Society of Cardiology. Europace. 2025;27:euaf076. doi:10.1093/europace/euaf076

Test yourself: antiarrhythmic drugs quiz50 questions with explanations · free
Start the test

Similar Posts